Norway's Borregaard Q4 revenue rises on BioMaterials unit strength

BORREGAARD ASA

04/02/2026 06:08

Overview

Norwegian specialty chemicals firm's Q4 revenue rose, but EBITDA missed analyst expectations

Company recorded NOK 245 mln impairment on bio-based start-ups

BioMaterials segment improved due to higher sales prices and lower costs

Outlook

Company did not provide specific guidance for future quarters or full year

Result Drivers

BIOMATERIALS PERFORMANCE - Higher sales prices and lower wood and energy costs improved BioMaterials results, offsetting other cost increases

BIOSOLUTIONS COSTS - Increased costs in BioSolutions offset high biovanillin deliveries and agricultural sales growth

FINE CHEMICALS DECLINE - Lower bioethanol sales prices affected Fine Chemicals, partially offset by strong fine chemical intermediates

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EBITDA
Miss
NOK 405 mln
NOK 421.64 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the specialty chemicals peer group is "buy"

Wall Street's median 12-month price target for Borregaard ASA is NOK220.00, about 13.8% above its February 3 closing price of NOK193.40

Press Release: ID:nGNE3fTbFD

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)